Comparison of acetylation phenotype with genotype coding for N- acetyltransferase (NAT2) in children

Pediatric Research

Volumn 45, Issue 3, 1999, Pages 403-408

  Zielińska, Elzbieta ^a   Bodalski, Jerzy ^a   Niewiarowski, Wojciech ^b   Bolanowski, Wojciech ^a   Matusiak, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ACYLTRANSFERASE; CAFFEINE;

ACETYLATOR PHENOTYPE; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INFANT; MALE; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; URINALYSIS; XENOBIOTIC METABOLISM;

EID: 0345004846     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-199903000-00019     Document Type: Article

References (42)

1. Clark DWJ 1985 Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 29:342-375
2. Hein DW, Rustan TD, Doll MA, Bucher KD, Ferguson RJ, Feng Y, Furman EJ, Gray K 1992 Acetyltransferases and susceptibility to chemicals. Toxicol Lett 64/65:123-130
3. Grant DM, Blum M, Meyer UA 1992 Polymorphisms of N-acetyltransferase genes. Xenobiotica 22:1073-1081
4. Meyer UA 1994 Polymorphism of human acetyltransferases. Environ Health Perspect 102(suppl 6):213-216
5. Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J 1994 Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 56:202-209
6. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I 1995 Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592
7. Blum M, Demierre A, Grant DM, Heim M, Meyer UA 1991 Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88:5237-5241
8. da Silva Pontes BV, Vincent-Viry M. Gueguen R, Galteau MM, Siest G 1993 Acelylation phenotypes and biological variation in a French Caucasian population. Eur J Clin Chem Clin Biochem 31:59-68
9. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP 1991 Prominence of slow acetylator phenotype among patients with sulfonamidc hypersensitivity reactions. Clin Pharmacol Ther 49:13-17
10. Grant DM, Tang BK, Kalow W 1983 Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355-359
11. Relling MV, Lin JS, Avers GD, Evans WE 1992 Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities. Clin Pharmacol Ther 52:643-658
12. Grant DM, Tang BK, Kalow W 1984 A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17:459-464
13. Klebovich I, Arvela P, Pelkonen O 1993 HPLC method for rapid determination of acetylator phenotype by measuring urinary caffeine metabolites. J Pharm Biomed Anal 11:1017-1021
14. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR 1989 Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmcol Ther 45:568-573
15. Rasmussen BB, Brîsen K 1996 Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 18:254-262
16. Rane A 1995 The major physiological factors that modulate drug metabolism in man. Implications for drug effects and toxicity. In: Pacifici GM, Fracchia GN (eds) Advances in Drug Metabolism in Man. Office for Official Publication of the European Communities, Brussels, pp 149-175
17. Pariente-Khayat A, Pons G, Richard MO, D'athis PH, Moran C, Badoual J, Olive G 1991 Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 29:492-495
18. Grant DM, Tang BK, Kalow W 1983 Variability in caffeine metabolism. Clin Pharmacol Ther 33:591-602
19. Deguchi T 1992 Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 267:18140-18147
20. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DAP, Grant DM. Hein DW, Hickman D, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y 1995 Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17
21. Kalow W, Tang BK 1991 Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
22. Carrillo JA, Benítez J 1994 Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 55:293-304
23. Ullrich D, Compagnone D, Münch B, Brandes A, Hille H, Bircher J 1992 Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations. Eur J Clin Pharmacol 43:167-172
24. Lorenzo B, Reidenberg MM 1989 Potential artifacts in the use of caffeine to determine acetylation phenotype. Br J Clin Pharmacol 28:207-208
25. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W 1991 Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49:648-657
26. Cribb AE, Isbrucker R, Levatte T, Tsui B. Gillespie CT, Renton KW 1994 Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with marker of systemic NAT1 activity. Pharmacogenetics 4:166-170
27. Leeder JS, Kearns GL 1997 Pharmacogenetics in pediatrics. Implications for practice. In: Bailey B., Koren G (eds) The Pediatric Clinics of North America. New Frontiers in Pediatric Drug Therapy. WB Saunders Company, Philadelphia, pp 55-77
28. Hayashi S, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K 1994 Interiń dividual differences in expression of human Ah receptor and related P450 genes. Carcinogenesis 15:801-806
29. Ha HR, Chen J, Krähenbühl S, Follath H 1996 Biotransformation of caffeine by cDNA-expressed human cytochromes P-450. Eur J Clin Pharmacol 49:309-315
30. Hickman D, Sim E 1991 N-acetyltransferase polymorphism. Comparison of phenó type and genotype in humans. Biochem Pharmacol 42:1007-1014
31. Mashimo M, Suzuki T, Abe M, Deguchi T 1992 Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 90:139-143
32. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I 1996 Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in Polish population. Clin Pharmacol Ther 59:376-382
33. Graf T, Broly F, Hoffman F, Probst M, Meyer UA, Howald H 1992 Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA tests in healthy human volunteers. Eur J Clin Pharmacol 43:399-403
34. Zylber-Katz E, Caraco Y, Granit L, Levy M 1995 Dipyrone metabolism in liver di'sease. Clin Pharmacol Ther 58:198-209
35. Walson PH, Edge J 1996 Clonazepam disposition in pediatric patients. Ther Drug Monit 18:1-5
36. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T 1994 Dapsone N-acetylation, metoprolol α-hydroxylation, and S-mephenytoin 4-hydroxylation polý morphisms in an Indonesian population: a cocktail and extended phenotyping assesś ment trial. Clin Pharmacol Ther 56:142-53
37. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tamgawara Y 1997 Genotyping of N-acetylation polymorphism and correlation with procainamide mé tabolism. Clin Pharmacol Ther 61:509-517
38. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB 1993 Phase I study of aminofide dosing based on acetylator phenotype. Cancer Res 53:2304-2308
39. Wolkenstein P. Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M 1995 A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenet́ ics 5:255-258
40. Cascorbi I, Brockmöller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I 1996 Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a suś ceptibility factor for lung cancer. Cancer Res 56:3961-3966
41. Veneis P, Bartsch H, Caporaso N, Harrington AM. Kadlubar FF, Landi MT, Malaveile CH, Shields PG, Skipper P, Talasaka G, Tannenbaum S 1994 Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369:154-156
42. Zieliriska E, Niewiarowski W, Bodalski J, Stańczyk A, Bolanowski W, Rȩbowski G 1997 Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 62:635-642